BACKGROUND: We have previously described the essential role of the retinoid-inducible nuclear factor (RINF) during differentiation of hematopoietic cells and suggested its putative involvement in myeloid leukemia and preleukemia. Here, we have investigated whether this gene could have a deregulated expression in malignant tissues compared with their normal tissues of origin and if this potential deregulation could be associated with important clinicopathological parameters. PATIENTS AND METHODS: RINF messenger RNA expression was examined in biopsies from locally advanced breast tumors, metastatic malignant melanomas, and papillary thyroid carcinomas and compared with their paired or nonpaired normal reference samples. Further, the prognostic role of RINF expression was evaluated in locally advanced breast cancer. RESULTS: RINF expression was significantly higher in all tumor forms (primary breast, and thyroid cancers and metastatic melanomas) as compared with normal control tissues (P < 0.001 for each comparison). Importantly, high levels of RINF expression correlated to a poor overall survival in breast cancer (P = 0.013). This finding was confirmed in three independent public microarray datasets (P = 0.043, n = 234; P = 0.016, n = 69; P = 0.001, n = 196) and was independent of tamoxifen therapy. Notably, high levels of RINF was strongly associated with TP53 wild-type status (P = 0.002) possibly indicating that high levels of RINF could substitute for TP53 mutations as an oncogenic mechanism during the malignant development of some cases of breast cancer. CONCLUSIONS: Our data indicate that (i) RINF overexpression is associated with the malignant phenotype in solid tumors and (ii) RINF overexpression represents an independent molecular marker for poor prognosis in breast tumors.
BACKGROUND: We have previously described the essential role of the retinoid-inducible nuclear factor (RINF) during differentiation of hematopoietic cells and suggested its putative involvement in myeloid leukemia and preleukemia. Here, we have investigated whether this gene could have a deregulated expression in malignant tissues compared with their normal tissues of origin and if this potential deregulation could be associated with important clinicopathological parameters. PATIENTS AND METHODS: RINF messenger RNA expression was examined in biopsies from locally advanced breast tumors, metastatic malignant melanomas, and papillary thyroid carcinomas and compared with their paired or nonpaired normal reference samples. Further, the prognostic role of RINF expression was evaluated in locally advanced breast cancer. RESULTS:RINF expression was significantly higher in all tumor forms (primary breast, and thyroid cancers and metastatic melanomas) as compared with normal control tissues (P < 0.001 for each comparison). Importantly, high levels of RINF expression correlated to a poor overall survival in breast cancer (P = 0.013). This finding was confirmed in three independent public microarray datasets (P = 0.043, n = 234; P = 0.016, n = 69; P = 0.001, n = 196) and was independent of tamoxifen therapy. Notably, high levels of RINF was strongly associated with TP53 wild-type status (P = 0.002) possibly indicating that high levels of RINF could substitute for TP53 mutations as an oncogenic mechanism during the malignant development of some cases of breast cancer. CONCLUSIONS: Our data indicate that (i) RINF overexpression is associated with the malignant phenotype in solid tumors and (ii) RINF overexpression represents an independent molecular marker for poor prognosis in breast tumors.
Authors: Myunggon Ko; Jungeun An; Hozefa S Bandukwala; Lukas Chavez; Tarmo Aijö; William A Pastor; Matthew F Segal; Huiming Li; Kian Peng Koh; Harri Lähdesmäki; Patrick G Hogan; L Aravind; Anjana Rao Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Andrea Kühnl; Peter J M Valk; Mathijs A Sanders; Adam Ivey; Robert K Hills; Ken I Mills; Rosemary E Gale; Martin F Kaiser; Richard Dillon; Melanie Joannides; Amanda Gilkes; Torsten Haferlach; Susanne Schnittger; Estelle Duprez; David C Linch; Ruud Delwel; Bob Löwenberg; Claudia D Baldus; Ellen Solomon; Alan K Burnett; David Grimwade Journal: Blood Date: 2015-03-24 Impact factor: 22.113
Authors: Floriana Centritto; Gabriela Paroni; Marco Bolis; Silvio Ken Garattini; Mami Kurosaki; Maria Monica Barzago; Adriana Zanetti; James Neil Fisher; Mark Francis Scott; Linda Pattini; Monica Lupi; Paolo Ubezio; Francesca Piccotti; Alberto Zambelli; Paola Rizzo; Maurizio Gianni'; Maddalena Fratelli; Mineko Terao; Enrico Garattini Journal: EMBO Mol Med Date: 2015-07 Impact factor: 12.137